Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : T/FIF Portfolio -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (141)	10/21/1998 7:49:00 PM
From: seminole	Read Replies (1) \| Respond to of 1073

Richard I hope I can make a small contribution to this site and I hope you keep MOGN in your portfolio. Cancer of the pancreas is the fifth leading cause of cancer death in the United States. This year approximately 27,000 Americans will die from cancer of the pancreas. The disease is not only common, but it is also extremely difficult to treat. For these and other reasons, cancer of the pancreas has been called "the challenge of the nineties" MGI Pharma Inc. said Tuesday it began a phase II study of its MGI 114 drug to treat prostate cancer and expects to begin phase II trials of the drug to treat ovarian and pancreatic cancer before the end of the year. MGI said that in patients treated with the currently recommended dose of the drug, a tumor shrunk more than 50 percent in a pancreatic cancer patient; another tumor shrunk less than 50 percent in a patient with cancer of the thymus; and tumors in five other patients remained unchanged during the four-month course of treatment. biz.yahoo.com richard